Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival
At first glance, you might not be too impressed with the data from Dermavant’s Phase IIIs for their psoriasis contender tapinarof. The results pale in comparison to the biologics that have been transforming the field.
But Dermavant, a brainchild of biotech entrepreneur Vivek Ramaswamy, isn’t about to go toe-to-toe with the heavyweights. Their cream treatment has a distinct commercial plan in place that leaves the most severe cases to the biologics, while positioning itself in the front of the market — and quite possibly in combination with some of those blockbusters that have been stealing all the headlines.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.